share_log

ACHV: First Quarter 2022 Results

ACHV: First Quarter 2022 Results

ACHV:2022年第一季度業績
Benzinga Real-time News ·  2022/05/13 10:56
By John Vandermosten, CFA
約翰·範德莫斯滕,CFA
NASDAQ:ACHV
納斯達克:非典病毒
READ THE FULL ACHV RESEARCH REPORT
閲讀ACHV研究報告全文
Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported first quarter 2022 results in a press release and held a conference call after market close on May 12, 2022. The company concurrently filed its Form 10-Q with the SEC. Highlights for 2022 include impressive topline results from the ORCA-21 trial, launch of the ORCA-3 trial, participation in various investor and scientific conferences and expansion of its manufacturing and quality and operations team and a board member addition.
成就生命科學公司(納斯達克:ACHV)在新聞稿中公佈了2022年第一季度業績,並於2022年5月12日收盤後召開了電話會議。該公司同時向美國證券交易委員會提交了10-Q表格。2022年的亮點包括ORCA-2令人印象深刻的背線結果1此外,我們還參與了ORCA-3試驗,參加了各種投資者和科學會議,擴大了製造、質量和運營團隊,並增加了一名董事會成員。
Achievements for the first quarter ended March 31st and to-date include:
截至3月31日的第一季度和到目前為止的成就包括:
➢ ORCA-2 last subject, last follow up...
➢ORCA-...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論